Connect Biopharma Holdings Limited (NASDAQ: CNTB) is a clinical-stage biopharmaceutical company advancing rademikibart, an anti-IL-4Rα antibody, in Phase 2 trials for acute asthma and COPD exacerbations, with recent enrollment completion and stock volatility reflecting clinical progress amid micro-cap biotech risks.
Fact: Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its lead candidate is rademikibart, a next-generation human monoclonal IgG4 antibody targeting interleukin-4 receptor alpha (IL-4Rα).[web:0][web:4]
Interpretation: The company positions itself in a high-unmet-need area (acute exacerbations), potentially differentiating from existing therapies like dupilumab through rapid onset and safety profile, though success depends on Phase 2/3 outcomes.
Uncertainty: Exact founding year varies slightly across sources; pipeline evolution reflects typical biotech pivots toward lead asset.
Interpretation: Positive clinical momentum (enrollment completion, no sample size adjustment) may support near-term catalysts with topline data expected in 2026, though cash burn and dilution risks persist for micro-caps.
| Metric | Value (as of ~July 9, 2026) |
|---|---|
| Recent Price | ~$2.22 - $2.58 (volatile; spiked ~16-23% intraday recently) |
| Market Cap | ~$140M - $167M |
| 52-Week Range | $1.05 - $3.82 |
| YTD Return | ~5.67% |
| 1-Year Return | ~95% - 144% |
| IPO Date / All-Time High | March 2021 / $28.50 (Aug 2021) |
| Volume (recent) | 600K - 1.7M shares |
Fact: Stock has shown high volatility typical of clinical-stage biotechs, with significant gains in the past year but substantial decline from post-IPO peaks.[web:33][web:31]
Data Limitation: Prices are snapshots and fluctuate rapidly; historical data from Yahoo Finance/Nasdaq; no dividends (biotech typical).